• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Aspirin comparable to rivaroxaban for extended venous thromboembolism prophylaxis following arthroplasty: The EPCAT II trial

byDayton McMillan
February 22, 2018
in Cardiology, Chronic Disease, Emergency, Imaging and Intervention, Public Health, Pulmonology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients initially treated with rivaroxaban following total knee or hip arthroplasty experienced similar rates of venous thromboembolism (VTE) regardless of continued rivaroxaban use or switching to aspirin for extended VTE prophylaxis.

2. No significant difference in rates of major bleeding complications was observed between aspirin and rivaroxaban treated groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: VTE is a serious adverse event following knee or hip arthroplasty. Use of prophylactic anticoagulants has reduced morbidity when administered both immediately after and for extended periods following surgery. While direct oral anticoagulants are often prescribed for extended VTE prophylaxis in part due to patient convenience, use of aspirin may provide a more cost-effective option. The EPCAT II (Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II) trial compares effectiveness and safety profiles of aspirin to rivaroxaban for use in extended VTE prophylaxis. At 90 days post total hip or knee arthroplasty, no difference in rates of VTE was observed between the aspirin and rivaroxaban groups. Additionally, no difference in bleeding complications was observed between the groups.

Strengths of the study include its large sample size and high rate of patient follow-up, and a limitation includes lack of comparison of VTE strategies immediately post-operatively. This study provides strong evidence supporting the use of aspirin as a cost-effective medication with comparable safety and efficacy profiles to rivaroxaban for extended VTE prophylaxis in arthroplasty patients.

Click to read the study in NEJM

Relevant Reading: Aspirin for prevention and treatment of venous thromboembolism

RELATED REPORTS

Aspirin discontinuation at 24 to 28 weeks gestation does not affect preeclampsia in high-risk patients

#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures

Variations in the use of cemented implants for hip fracture repair in Nova Scotia

In-Depth [randomized controlled trial]: This multicenter, randomized, controlled trial was conducted between 2013 and 2016. Eligible patients were undergoing unilateral total hip or knee arthroplasty, and those with recent fractures or metastatic cancer were excluded. Patients (n = 3427) received rivaroxaban following surgery until postoperative day 5 and were then randomized to receive either rivaroxaban (n = 1718) or aspirin (n = 1719). Knee arthroplasty patients received 9 days of extended VTE prophylaxis and those who underwent hip arthroplasty received 30 days of prophylaxis. The primary outcome was symptomatic VTE within 90 days, and the main safety outcome was significant bleeding rate.

VTE occurred in 0.64% of patients in the aspirin group and 0.70% of rivaroxaban treated patients (difference, 0.06 percentage points; 95% confidence interval [CI], –0.55 to 0.66; aspirin noninferiority, p < 0.001; aspirin superiority, p = 0.84). Major bleeding occurred at similar rates in 0.47% and 0.29% of aspirin and rivaroxaban treated patients, respectively (difference, 0.18 percentage points; 95% CI, −0.65 to 0.29; p = 0.42), with most bleeding occurring within 10 days post-operatively. Rates of VTE and bleeding did not significantly differed between patients undergoing total hip or knee arthroplasty.

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspirinhip arthroplastyrivaroxabantotal knee replacementvenous thromboembolism
Previous Post

Thrombectomy improves functional outcomes for imaging screened patients 6 to 16 hours after stroke: The DEFUSE 3 trial

Next Post

Anthropometric failure in children related to intra-population variation in health determinants

RelatedReports

Prenatal antidepressant exposure may increase risk of poor motor development
Chronic Disease

Aspirin discontinuation at 24 to 28 weeks gestation does not affect preeclampsia in high-risk patients

February 21, 2023
#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
StudyGraphics

#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures

February 2, 2023
Bisphosphonate use and risk of atypical femur fractures
Orthopedic Surgery

Variations in the use of cemented implants for hip fracture repair in Nova Scotia

December 19, 2022
Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

November 29, 2022
Next Post
Anthropometric failure in children related to intra-population variation in health determinants

Anthropometric failure in children related to intra-population variation in health determinants

Meeting families, demographic information affect child abuse work-up

Oral neonatal rotavirus vaccine RV3-BB effective in preventing severe gastroenteritis

Topical analgesia for dyspareunia effective in breast cancer survivors

First-degree family history of breast cancer associated with increased risk of breast cancer in older women

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
  • Patients with early pregnancy loss less likely to receive active management in the emergency department
  • Mycobacterium abscessus infections after cardiac surgery linked to hospital water system
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options